Celltrion confirms neutralising potency against emerging SARS-CoV-2 variants with anti-COVID-19 monoclonal antibody treatment regdanvimab (CT-P59)

Must Read

Celltrion Group today announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed neutralising potency against emerging variants first identified in New York (B.1.526), Nigeria (B.1.525) and …

Latest News

Govt ensured mental health and elderly daycare covered by BPJS

Jakarta (ANTARA) - Indonesia's Ministry of Health called for mental health services, including those provided by clinical psychologists and...

More Articles Like This